Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener klinische Wochenschrift Education
Erschienen in:

01.11.2013

Lebertransplantation

verfasst von: Prim. Univ. Prof. Dr. Ivo Graziadei

Erschienen in: Wiener klinische Wochenschrift Education | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Auszug

Die Organtransplantation ist heute ein international etabliertes Therapieprinzip, welches aus der modernen Medizin nicht mehr wegzudenken ist. Der Erfolg der Organtransplantation ist absolut von der Spenderfreudigkeit der Bevölkerung abhängig. Obwohl die Organtransplantation eine große Belastung für das Gesundheitsbudget darstellt, gibt es kein vergleichbares Verfahren in der Medizin mit so einem enormen Gewinn an Lebensqualität. …
Nächster Artikel Pankreatitis - ein Überblick
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Keeffe EB. Patient selection and listing policies for liver transplantation. J Gastroenterol Hepatol. 1999;14(Suppl):S42–7.
2.
3.
D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217–31.PubMedCrossRef
4.
Murray KF, Carithers RL Jr. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology. 2005;41:1407–32.PubMedCrossRef
5.
Graziadei I. Liver transplantation organ allocation between child and MELD. Wien Med Wochenschr. 2006;156:410–15.PubMedCrossRef
6.
Finkenstedt A, Nachbaur K, Zoller H, et al. Acute on chronic liver failure: excellent outcome after liver transplantation but high mortality on the wait list. Liver Transpl. 2013;19:879–86.PubMedCrossRef
7.
Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249–53.PubMedCrossRef
8.
Lucey MR. Liver transplantation in patients with alcoholic liver disease. Liver Transpl. 2011;17:751–9.PubMedCrossRef
9.
DiMartini A, Dew MA, Chaiffetz D, et al. Early trajectories of depressive symptoms after liver transplantation for alcoholic liver disease predicts long-term survival. Am J Transplant. 2011;11:1287–95.PubMedCrossRef
10.
Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.PubMedCrossRef
11.
Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394–403.PubMedCrossRef
12.
Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.PubMedCrossRef
13.
Clavien PA, Lesurtel M, Bossuyt PM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11–22.
14.
Maddala YK, Stadheim L, Andrews JC, et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl. 2004;10:449–55.PubMedCrossRef
15.
Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30:1434–40.PubMedCrossRef
16.
Graziadei IW, Sandmueller H, Waldenberger P, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl. 2003;9:557–63.PubMedCrossRef
17.
Majno P, Lencioni R, Mornex F, et al. Is the treatment of hepatocellular carcinoma on the waiting list necessary? Liver Transpl. 2011;17(Suppl 2):S98–108.
18.
Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329:1842–7.PubMedCrossRef
19.
Roche B, Samuel D. Liver transplantation for hepatitis B virus-related liver disease: indications, prevention of recurrence and results. J Hepatol. 2003;39(Suppl 1):S181–9.
20.
Lucey MR, Terrault N, Ojo L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013;19:3–26.PubMedCrossRef
21.
Angus PW, Patterson SJ. Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen? Liver Transpl. 2008;14(Suppl 2):S15–22.
22.
Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Am J Transplant. 2013;13:353–62.PubMedCrossRef
23.
Bohorquez HE, Cohen AJ, Girgrah N, et al. Liver transplantation in hepatitis B core-negative recipients using livers from hepatitis B core-positive donors: a 13-year experience. Liver Transpl. 2013;19:611–18.PubMedCrossRef
24.
Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl. 2003;9:63–6.CrossRef
25.
Graziadei IW, Zoller HM, Schloegl A, et al. Early viral load and recipient interleukin-28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation. Liver Transpl. 2012;18:671–9.PubMedCrossRef
26.
Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl. 2002;8:14–8.CrossRef
27.
Neuberger J. Treatment of hepatitis C virus infection in the allograft. Liver Transpl. 2003;9:101–8.CrossRef
28.
Roche B, Samuel D. Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int. 2012;32(Suppl 1):120–8.PubMedCrossRef
29.
Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008;49:274–87.PubMedCrossRef
30.
Levitsky J, Fiel MI, Norvell JP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology. 2012;142:1132–39.e1.PubMedCrossRef
31.
Belli LS, Volpes R, Graziadei I, et al. Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study. Dig Liver Dis. 2012;44:603–09.PubMedCrossRef
32.
Veldt BJ, Poterucha JJ, Watt KD, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant. 2008;8:2426–33.PubMedCrossRef
33.
Verna EC, Burton JR, O’leary JG, et al. A multicenter study of protease inhibitor-triple therapy in HCV-infected liver transplant recipients: report from the CUSH-C group. J Hepatol. 2013;58:10s(abstr 23).
34.
Coilly A, Dumortier J, Botta-Fridlund J, et al. End of treatment response after protease inhibitor based therapy for hepatitis C recurrence after liver transplantation: a multicentric European experience. J Hepatol. 2013;58: 572s(abstr 1422).
35.
Fontana RJ, Hughes EA, Bifano M, et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant. 2013;13:1601–5.PubMedCrossRef
36.
Burra P, Senzolo M, Adam R, et al. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am J Transplant. 2010;10:138–48.PubMedCrossRef
37.
Neuberger J, Schulz KH, Day C, et al. Transplantation for alcoholic liver disease. J Hepatol. 2002;36:130–7.PubMedCrossRef
38.
Burra P, Mioni D, Cecchetto A, et al. Histological features after liver transplantation in alcoholic cirrhotics. J Hepatol. 2001;34:716–22.PubMedCrossRef
39.
Duclos-Vallee JC, Sebagh M. Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation. Liver Transpl. 2009;15(Suppl 2):S25–34.
40.
Liermann Garcia RF, Evangelista Garcia C, McMaster P, et al. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology. 2001;33:22–7.PubMedCrossRef
41.
Graziadei IW, Wiesner RH, Batts KP, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology. 1999;29:1050–56.PubMedCrossRef
42.
Fosby B, Karlsen TH, Melum E. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol. 2012;18:1–15.PubMedCrossRef
43.
Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33:1080–6.PubMedCrossRef
44.
Millonig G, Graziadei IW, Freund MC, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2007;13:272–9.PubMedCrossRef
45.
Otto G, Herber S, Heise M, Lohse AW, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl. 2006;12:1260–7.PubMedCrossRef
46.
Darwish Murad S, Kim WR, Harnois DM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012;143:88–98.e3(quiz e14).
47.
Graziadei IW, Schwaighofer H, Koch R, et al. Long-term outcome of endoscopic treatment of biliary strictures after liver transplantation. Liver Transpl. 2006;12:718–25.PubMedCrossRef
48.
Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation. 2001;72:1934–9.PubMedCrossRef
49.
Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931–40.PubMedCrossRef
50.
Herrero JI. De novo malignancies following liver transplantation: impact and recommendations. Liver Transpl. 2009;15(Suppl 2):S90–4.
51.
Watt KD, Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol. 2010;53:199–206.PubMedCrossRef
52.
Guichelaar MM, Schmoll J, Malinchoc M, et al. Fractures and avascular necrosis before and after orthotopic liver transplantation: long-term follow-up and predictive factors. Hepatology. 2007;46:1198–207.PubMedCrossRef
53.
Millonig G, Graziadei IW, Eichler D, et al. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Transpl. 2005;11:960–6.PubMedCrossRef
54.
Chandok N, Watt KD. Burden of de novo malignancy in the liver transplant recipient. Liver Transpl. 2012;18:1277–89.PubMedCrossRef
55.
Collett D, Mumford L, Banner NR, et al. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant. 2010;10:1889–96.PubMedCrossRef
56.
Engels EA, Pfeiffer RM, Fraumeni JF Jr., et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306:1891–901.PubMedCrossRef
57.
Finkenstedt A, Graziadei IW, Oberaigner W, et al. Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients. Am J Transplant. 2009;9:2355–61.PubMedCrossRef
58.
Sanchez-Fueyo A. Hot-topic debate on tolerance: immunosuppression withdrawal. Liver Transpl. 2011;17(Suppl 3):S69–73.
59.
Sanchez-Fueyo A, Strom TB. Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs. Gastroenterology. 2011;140:51–64.PubMedCrossRef
60.
Benitez C, Londono MC, Miquel R, et al. Prospective multi-center clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology. 2013 (in press).
61.
Dutkowski P, De Rougemont O, Mullhaupt B, et al. Current and future trends in liver transplantation in Europe. Gastroenterology. 2010;138:802–809.e1–4.
62.
Burra P, Samuel D, Wendon J, et al. Strategies for liver support: from stem cells to xenotransplantation. J Hepatol. 2004;41:1050–9.PubMedCrossRef
63.
Muraca M. Evolving concepts in cell therapy of liver disease and current clinical perspectives. Dig Liver Dis. 2011;43:180–7.PubMedCrossRef
Metadaten
Titel
Lebertransplantation
verfasst von
Prim. Univ. Prof. Dr. Ivo Graziadei
Publikationsdatum
01.11.2013
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift Education / Ausgabe 2/2013
Print ISSN: 1863-3579
Elektronische ISSN: 1863-3765
DOI
https://doi.org/10.1007/s11812-013-0059-1

Weitere Artikel der Ausgabe 2/2013